Indoco Remedies Management
Management criteria checks 2/4
Indoco Remedies' CEO is Sundeep Bambolkar, appointed in Feb 2012, has a tenure of 13.83 years. total yearly compensation is ₹80.57M, comprised of 63.6% salary and 36.4% bonuses, including company stock and options. directly owns 0.51% of the company’s shares, worth ₹119.78M. The average tenure of the management team and the board of directors is 9 years and 18.7 years respectively.
Key information
Sundeep Bambolkar
Chief executive officer
₹80.6m
Total compensation
| CEO salary percentage | 63.65% |
| CEO tenure | 13.8yrs |
| CEO ownership | 0.5% |
| Management average tenure | 9yrs |
| Board average tenure | 18.7yrs |
Recent management updates
Recent updates
Here's Why Shareholders Should Examine Indoco Remedies Limited's (NSE:INDOCO) CEO Compensation Package More Closely
Sep 05
Earnings Update: Here's Why Analysts Just Lifted Their Indoco Remedies Limited (NSE:INDOCO) Price Target To ₹259
Jul 27Indoco Remedies Limited (NSE:INDOCO) Soars 27% But It's A Story Of Risk Vs Reward
Jul 01Revenues Working Against Indoco Remedies Limited's (NSE:INDOCO) Share Price Following 25% Dive
Jan 29
Plant Remediation And Clarity Pharma Partnership Will Support Future Market Expansion
Resolving manufacturing plant issues is critical for increasing U.S. market supply, boosting revenue, and minimizing compliance risks.₹294: That's What Analysts Think Indoco Remedies Limited (NSE:INDOCO) Is Worth After Its Latest Results
Jan 24Indoco Remedies Limited Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected
Oct 27Earnings Troubles May Signal Larger Issues for Indoco Remedies (NSE:INDOCO) Shareholders
May 24Earnings Miss: Indoco Remedies Limited Missed EPS By 56% And Analysts Are Revising Their Forecasts
Jan 26Does Indoco Remedies (NSE:INDOCO) Have A Healthy Balance Sheet?
Jan 26We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Indoco Remedies Limited's (NSE:INDOCO) CEO For Now
Sep 16Here's Why Indoco Remedies (NSE:INDOCO) Can Manage Its Debt Responsibly
May 21Indoco Remedies (NSE:INDOCO) Has Announced That It Will Be Increasing Its Dividend To ₹1.50
Aug 31Indoco Remedies (NSE:INDOCO) Has Announced That It Will Be Increasing Its Dividend To ₹1.50
Jul 04Does Indoco Remedies (NSE:INDOCO) Deserve A Spot On Your Watchlist?
Jul 02Indoco Remedies (NSE:INDOCO) Seems To Use Debt Quite Sensibly
Jun 10Does Indoco Remedies (NSE:INDOCO) Deserve A Spot On Your Watchlist?
Mar 25Indoco Remedies Limited's (NSE:INDOCO) Intrinsic Value Is Potentially 21% Below Its Share Price
Mar 09What Percentage Of Indoco Remedies Limited (NSE:INDOCO) Shares Do Insiders Own?
Feb 22Did You Miss Indoco Remedies' (NSE:INDOCO) 37% Share Price Gain?
Feb 07Indoco Remedies Limited's (NSE:INDOCO) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?
Jan 17CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2025 | n/a | n/a | -₹1b |
| Jun 30 2025 | n/a | n/a | -₹1b |
| Mar 31 2025 | ₹81m | ₹51m | -₹737m |
| Dec 31 2024 | n/a | n/a | -₹107m |
| Sep 30 2024 | n/a | n/a | ₹321m |
| Jun 30 2024 | n/a | n/a | ₹767m |
| Mar 31 2024 | ₹76m | ₹47m | ₹985m |
| Dec 31 2023 | n/a | n/a | ₹1b |
| Sep 30 2023 | n/a | n/a | ₹1b |
| Jun 30 2023 | n/a | n/a | ₹1b |
| Mar 31 2023 | ₹65m | ₹40m | ₹1b |
| Dec 31 2022 | n/a | n/a | ₹2b |
| Sep 30 2022 | n/a | n/a | ₹2b |
| Jun 30 2022 | n/a | n/a | ₹2b |
| Mar 31 2022 | ₹46m | ₹30m | ₹2b |
| Dec 31 2021 | n/a | n/a | ₹1b |
| Sep 30 2021 | n/a | n/a | ₹1b |
| Jun 30 2021 | n/a | n/a | ₹1b |
| Mar 31 2021 | ₹28m | ₹20m | ₹930m |
| Dec 31 2020 | n/a | n/a | ₹734m |
| Sep 30 2020 | n/a | n/a | ₹571m |
| Jun 30 2020 | n/a | n/a | ₹393m |
| Mar 31 2020 | ₹18m | ₹15m | ₹241m |
| Dec 31 2019 | n/a | n/a | ₹302m |
| Sep 30 2019 | n/a | n/a | ₹264m |
| Jun 30 2019 | n/a | n/a | ₹111m |
| Mar 31 2019 | ₹15m | ₹12m | -₹29m |
Compensation vs Market: Sundeep's total compensation ($USD893.30K) is above average for companies of similar size in the Indian market ($USD189.40K).
Compensation vs Earnings: Sundeep's compensation has increased whilst the company is unprofitable.
CEO
Sundeep Bambolkar (65 yo)
Mr. Sundeep Vasant Bambolkar has been a Joint Managing Director at Indoco Remedies Limited since February 15, 2012. Mr. Bambolkar served as Chief Financial Officer at Indoco Remedies Limited from March 23,...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Non-Executive Chairman & Whole time Director | 62.4yrs | ₹200.00k | 4.7% ₹ 1.1b | |
| Joint MD & Executive Director | 13.8yrs | ₹80.57m | 0.51% ₹ 119.8m | |
| MD & Executive Director | 13.8yrs | ₹91.07m | 6.17% ₹ 1.5b | |
| Chief Financial Officer | 4.1yrs | ₹19.01m | no data | |
| Head of Legal | 3yrs | ₹6.46m | no data | |
| Vice President of Operations | no data | no data | no data | |
| Chief Technical Officer | no data | ₹7.57m | no data | |
| President of Sales & Marketing | no data | no data | no data | |
| Chief Marketing Officer | no data | no data | no data | |
| Vice President of Corporate HR | no data | no data | no data | |
| Head Formulation of Planning & Operations | no data | no data | no data | |
| Executive Vice President of International Business for Regulated Markets | no data | no data | no data |
Experienced Management: INDOCO's management team is seasoned and experienced (9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Non-Executive Chairman & Whole time Director | 62.4yrs | ₹200.00k | 4.7% ₹ 1.1b | |
| Joint MD & Executive Director | 21.8yrs | ₹80.57m | 0.51% ₹ 119.8m | |
| MD & Executive Director | 21.8yrs | ₹91.07m | 6.17% ₹ 1.5b | |
| Independent Non-Executive Director | 20.7yrs | ₹580.00k | no data | |
| Independent Non-Executive Director | 18.7yrs | ₹660.00k | no data | |
| Non-Executive Director | 11.6yrs | ₹260.00k | no data | |
| Non-Executive & Independent Director | 5.8yrs | ₹480.00k | no data | |
| Independent Non-Executive Director | 1.7yrs | ₹460.00k | no data | |
| Independent Non-Executive Director | 1.7yrs | ₹520.00k | no data |
Experienced Board: INDOCO's board of directors are seasoned and experienced ( 18.7 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/03 05:30 |
| End of Day Share Price | 2025/12/03 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Indoco Remedies Limited is covered by 14 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sriraam Rathi | Anand Rathi Shares and Stock Brokers Limited |
| Srivathsan Ramachandran | Avendus Spark |
| Rohit Bhat | Batlivala & Karani Securities India Pvt. Ltd. |